Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Würselen – page 114

1 367 clinical trials in Würselen, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Würselen at a glance
1 367
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 367 trials in Würselen

Open in trial search

Study of Pembrolizumab and Azacitidine for Patients with Acute Myeloid Leukemia Facing Imminent Relapse

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Technische Universitat Dresden

Asthma

Not recruiting

Study on Reducing Asthma Medication with Tezepelumab in Patients Aged 12 to 80 with Severe Asthma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tezepelumab
  • Sponsor:AstraZeneca AB

Study on Liposomal Irinotecan, Carboplatin, or Oxaliplatin for First-Line Treatment in Patients with Advanced Esophagogastric Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Amsterdam UMC Stichting

Major depression

Not recruiting

Study on Aticaprant for Adults with Major Depressive Disorder and Anhedonia Not Responding to Antidepressants

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Aticaprant
  • Sponsor:Janssen Cilag International

Crohn's disease

Not recruiting

Study on Guselkumab for Healing in Crohn's Disease Patients

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Crohn's disease

Not recruiting

Study of AZD7798 compared to placebo in patients with moderate to severe Crohn's disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD7798
  • Sponsor:AstraZeneca AB

Study on Ibrutinib and Drug Combination for Patients with Generalized Mantle Cell Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Ibrutinib
  • Sponsor:Klinikum Der Universitat Munchen AöR

Primary amyloidosis

Not recruiting

Study on Birtamimab and Bortezomib for Patients with Advanced Light Chain Amyloidosis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Birtamimab
  • Sponsor:Prothena Biosciences Limited

Nephropathy

Not recruiting

Study on the Effects of Povetacicept for Adults with IgA Nephropathy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Povetacicept
  • Sponsor:Alpine Immune Sciences Inc.

Study on Durvalumab for Patients with Completely Removed Non-Small Cell Lung Cancer

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Clinipace Global Limited

Colitis ulcerative

Not recruiting

Study of RO7790121 Treatment for Adults with Moderate to Severe Ulcerative Colitis: Testing Effectiveness and Safety in Initial and Long-term Therapy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Other cities in Germany

The busiest research cities in the country

All 503 cities in Germany

Clinical research in Würselen

What the registry says about research in the country

01 Urological Oncology

Innovative research focusing on non-muscle invasive bladder cancer, evaluating combination therapies including immunotherapy approaches. These trials aim to improve treatment outcomes and reduce recurrence rates.

  • BCG Combination Therapy
  • Novel Immunotherapy Approaches
  • Disease-Free Survival Studies

Examining alternative treatment options including natural compounds for bladder cancer management.

02 Hematologic Disorders

Advanced research into polycythemia vera treatment resistance, utilizing artificial intelligence to predict therapeutic outcomes. Studies focus on optimizing hydroxyurea treatment protocols.

  • AI-Driven Treatment Prediction
  • Drug Resistance Analysis
  • Personalized Medicine Approaches

Integration of machine learning technologies to enhance treatment effectiveness.

03 Prostate Cancer Research

Comparative studies evaluating different dosing regimens for metastatic prostate cancer treatments, focusing on optimizing therapeutic combinations while minimizing adverse effects.

  • Treatment Safety Profiles
  • Dosing Schedule Optimization
  • Combination Therapy Assessment

Investigating innovative approaches to enhance treatment tolerability and effectiveness.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.